Head to Head Survey: LivaNova (NASDAQ:LIVN) versus Dynatronics (NASDAQ:DYNT)

Dynatronics (NASDAQ:DYNT) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Risk & Volatility

Dynatronics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares Dynatronics and LivaNova”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60 million	0.00	-$2.70 million	($1.35)	N/A
LivaNova	$1.39 billion	3.21	-$242.47 million	$3.38	23.90

Dynatronics has higher earnings, but lower revenue than LivaNova. Dynatronics is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dynatronics and LivaNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
LivaNova	12.82%	16.35%	7.76%

Insider and Institutional Ownership

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Dynatronics and LivaNova, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0	0	0	0	0.00
LivaNova	0	4	6	1	2.73

LivaNova has a consensus price target of $83.50, suggesting a potential upside of 3.37%. Given LivaNova’s stronger consensus rating and higher possible upside, analysts clearly believe LivaNova is more favorable than Dynatronics.

Summary

LivaNova beats Dynatronics on 12 of the 14 factors compared between the two stocks.

About Dynatronics

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.